A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to September 2022.
| dc.contributor.author | Doucette, Emily Jayne | |
| dc.contributor.author | Kellner, James Duncan | |
| dc.date.accessioned | 2023-04-21T16:17:57Z | |
| dc.date.available | 2023-04-21T16:17:57Z | |
| dc.date.issued | 2023-04-19 | |
| dc.description | Funded by Government of Alberta and Alberta Children's Hospital Research Institute. | |
| dc.description.abstract | Introduction: Measurement of SARS-CoV-2 antibody seropositivity is important to accurately understand exposure to infection and/or vaccination in populations. Methods: A cohort of children with or without prior SARS-CoV-2 infections was enrolled in Calgary, Canada in 2020. Venous blood was sampled 4 times from July 2020 to April 2022 for SARS-CoV-2 nucleocapsid and spike antibodies, with an additional 5th visit in the fall of 2022. Demographic and clinical information was obtained including SARS-CoV-2 test results and vaccination records. Results and analysis: 1035 children were enrolled and 88.9% completed 4 visits; median age 9 years (IQR: 5,13); 519 (50.1%) female; and 815 (78.7%) Caucasian. 477 (46.1%) participants attended Visit 5. Before enrollment, 118 (11.4%) had confirmed or probable SARS-CoV-2 infection. By September 2022, the total cumulative percentage of previously uninfected participants diagnosed with COVID-19 was 53.9% by Visit 5. (0/917 (0%), 15/873 (1.7%), 31/837 (3.7%), 280/820 (34.1%), and 63/439 (14.4%) at Visits 1-5, respectively). Nucleocapsid antibody seropositivity declined to 18.0% after more than 200 days after diagnosis. In contrast, spike antibodies remained elevated in 97.6% of unvaccinated children after more than 400 days after diagnosis. By September 2022, 97.1% (232/239) of children 12 years and older, 85.9% (171/199) of children 5-11, and 15.4% (6/39) of children under 5 received at least 1 dose of vaccine. At that time, all 409 vaccinated children had spike antibodies, compared with 38/64 (59.4%) of unvaccinated children (P<0.001 for comparison of proportions). Conclusions: By September 2022, most children in the study had a serologic response against the SARS-CoV-2 virus from infection and/or vaccination, with unvaccinated children much less likely to have a serologic response. Ongoing studies of serologic status are needed to estimate population levels of virus exposure and durability of antibody response after infection and/or vaccination. | |
| dc.description.grantingagency | Other | |
| dc.identifier.uri | https://prism.ucalgary.ca/handle/1880/116091 | |
| dc.identifier.uri | https://dx.doi.org/10.11575/PRISM/dspace/40937 | |
| dc.language.iso | en | |
| dc.publisher | Canadian Immunization Conference | |
| dc.publisher.institution | University of Calgary | |
| dc.rights | Attribution-NonCommercial-NoDerivs 2.5 Canada | en |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/ca/ | |
| dc.subject | COVID-19 | |
| dc.subject | antibodies | |
| dc.subject | pediatrics | |
| dc.subject | vaccine | |
| dc.subject | serology | |
| dc.title | A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to September 2022. | |
| dc.title.alternative | AB3C | |
| dc.type | Other |